MRNA - Moderna, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
31.86
-0.56 (-1.73%)
At close: 4:00PM EDT

31.86 0.00 (0.00%)
After hours: 7:55PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close32.42
Open32.55
Bid31.83 x 1000
Ask31.99 x 1000
Day's Range31.32 - 32.92
52 Week Range11.54 - 36.00
Volume4,805,763
Avg. Volume13,543,736
Market Cap10.482B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.55
Earnings DateFeb 25, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • 4 Good Quality Sector ETFs & Stocks to Buy Right Now
      Zacks

      4 Good Quality Sector ETFs & Stocks to Buy Right Now

      These sectors are extremely well-positioned to survive market shocks. Buy the related ETFs and stocks.

    • Coronavirus Vaccine Developed In Short Time Unlikely To Be Safe, International Vaccine Institute Says
      Benzinga

      Coronavirus Vaccine Developed In Short Time Unlikely To Be Safe, International Vaccine Institute Says

      A novel coronavirus (COVID-19) vaccine developed and approved in a rush may prove to be unsafe, according to International Vaccine Institute Director-General Jerome Kim.What Happened "We don't know that a vaccine that's developed in four months -- or I guess 12 to 18 months, which is the current estimate -- is really safe," Kim told CNBC, as reported Thursday.According to Kim, it takes anywhere between five to 10 years to roll out vaccines using typical procedures.Kim further told CNBC that there had been a special urgency to develop a vaccine for COVID-19, with a majority of countries suffering the outbreak, and that has resulted in a "significant amount of funding" for pharmaceutical companies to develop a vaccine.It's "really a remarkable thing," the IVI head said, but warned that 93% of the vaccines fail clinical trials.Moderna Inc. (NASDAQ: MRNA) was the first company to begin clinical trials of its COVID-19 vaccine in April, followed recently by Inovio Pharmaceuticals Inc. (NASDAQ: INO). The phase one trial of Johnson & Johnson (NYSE: JNJ) is also expected to begin later this year.When asked about President Donald Trump's claim that antimalarial drugs hydroxychloroquine and chloroquine are helping for coronavirus patients, Kim told CNBC that more research and evidence is needed."We are going to hope to test this to make sure that either this allows people to get off ventilators quickly...or it keeps people out of hospitals..or that it decreases the period of time that a patient is infectious," Kim said, adding that the concern isn't just over the drug's safety.See more from Benzinga * Microsoft Delays Launch Of Dual-Screen Surface Neo To Next Year * 'I Am Trying To Get More Cash': Why Mark Cuban Isn't Hopeful On US Market Rally * Sen. Kelly Loeffler Will Liquidate Stocks 'To End The Distraction' Following Insider Trading Controversy(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Business Wire

      Moderna to Present at 19th Annual Needham Healthcare Conference

      Moderna to present at 19th Annual Needham Healthcare Conference.

    • Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress
      Zacks

      Biotech Stocks, ETFs to Gain on COVID-19 Vaccine & Drug Progress

      The race to introduce a vaccine and drug for COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.

    • The Zacks Analyst Blog Highlights: Moderna, Regeneron Pharmaceuticals, Zoom Video Communications, Peloton Interactive and Costco Wholesale
      Zacks

      The Zacks Analyst Blog Highlights: Moderna, Regeneron Pharmaceuticals, Zoom Video Communications, Peloton Interactive and Costco Wholesale

      The Zacks Analyst Blog Highlights: Moderna, Regeneron Pharmaceuticals, Zoom Video Communications, Peloton Interactive and Costco Wholesale

    • Ex-Obama adviser Dr. Emanuel explains what it will take for America to 'return to full normalcy'
      Yahoo Finance

      Ex-Obama adviser Dr. Emanuel explains what it will take for America to 'return to full normalcy'

      The U.S. reached a grim milestone on Monday, passing 10,000 coronavirus-related deaths, and according to a prominent physician, the nation won’t move beyond the crisis without a vaccine.

    • These Medical ETFs & Stocks Deserve a Salute on Health Day
      Zacks

      These Medical ETFs & Stocks Deserve a Salute on Health Day

      The World Health Day of 2020 puts these medical companies and the related stocks and ETFs in focus.

    • Business Wire

      Moderna to Host Virtual Vaccines Day on April 14, 2020

      Moderna to host virtual Vaccines Day on April 14, 2020.

    • Why You Might Want to Avoid 'Virus Stocks'
      GuruFocus.com

      Why You Might Want to Avoid 'Virus Stocks'

      Once economies begin to recover, stocks that have jumped due to the coronavirus will likely lose ground Continue reading...

    • Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
      Zacks

      Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

      Moderna (MRNA) closed at $34.64 in the latest trading session, marking a -0.57% move from the prior day.

    • Coronavirus update: New York possibly near apex, markets open the week higher
      Yahoo Finance

      Coronavirus update: New York possibly near apex, markets open the week higher

      Seemingly hopeful news came out of New York Monday, which could be nearing its apex of the novel coronavirus crisis, while markets opened higher to start a week that could see other metro areas surge in cases and deaths.

    • TheStreet.com

      Vir Biotechnology Soars on $250 Million GlaxoSmithKline Investment in Coronavirus Treatment

      Vir Biotechnology soars after GlaxoSmithKline says it will invest $250 million in the biotech company.

    • Moderna Stock Surges 78% YTD on Coronavirus Vaccine Progress
      Zacks

      Moderna Stock Surges 78% YTD on Coronavirus Vaccine Progress

      Moderna (MRNA) is making significant progress in development of coronavirus vaccine. It is actively preparing for a potential phase II study.

    • 5 Top Stocks to Buy With the $1,200 Coronavirus Stimulus Check
      Zacks

      5 Top Stocks to Buy With the $1,200 Coronavirus Stimulus Check

      A one-time $1,200 cash payment from the federal government is widely expected to arrive around the middle of April. Here's how to use it -

    • Mike Khouw's Moderna Options Trade
      Benzinga

      Mike Khouw's Moderna Options Trade

      On CNBC's "Options Action", Mike Khouw shared with the viewers his options trading idea for Moderna Inc (NASDAQ: MRNA), the company that is currently leading the race for a COVID-19 vaccine.The stock is trading close to its all-time high and the options premiums in the name are elevated, so Khouw wants to make a bullish bet by selling the May $30/$28 put spread for a credit of 80 cents. If the stock stays above $30 at the May expiration, Khouw is going to collect the premium. The trade starts to lose money below $29.20 and in case of a pullback to $28 or lower it would reach its maximal loss of $1.20.Extreme market volatility has pulled the rug out from under a lot of traders. Attend the virtual Benzinga Options Boot Camp to learn to trade options in a volatile market and start going after solid trades with absolute confidence. Register for FREE at benzingabootcamp.com before space fills up!See more from Benzinga * Tony Zhang's Nike Trade * Analysts Share Stocks They Would Buy In This Environment: Exxon Mobil, P&G And More * PIMCO CIO Says To Buy What The Fed Is Buying(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Barrons.com

      Coronavirus-Vaccine Hopes Have Lifted Moderna Stock. Planned Sales by Insiders Have Surged.

      The biotech’s shares are on the rise, and so are automated sales of Moderna shares through plans set up by company insiders.

    • Hilton Stock Will Rally Once This Crisis Passes
      InvestorPlace

      Hilton Stock Will Rally Once This Crisis Passes

      Shares of some of the world's best companies have been cut down amid the current crisis. Hilton Worldwide (NYSE:HLT) is no exception. Hilton stock has dropped a stunning 46% from its peak.Source: josefkubes / Shutterstock.com The fall is a classic case of the market weighing short-term fears too heavily. Of course Hilton is going to take a hit from the response to the coronavirus pandemic. But, again, its share price has been cut almost in half.That type of decline isn't justified by demand that is reduced for a few months. In fact, it's not even justified by an impact that lasts a few years.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe impact won't last a few years. This crisis will pass. The economy will recover. We will make it through. On the other side, consumers will want to travel and likely want to do so soon. (I'm surely not the only one with a strong case of 'cabin fever' at the moment.) * 7 Telecom Stocks That Are Worth a Close Look I'm not dismissing the very real human toll the coronavirus is taking. But the U.S. economy, and U.S. stocks, will come back stronger than ever. In the meantime, investors have the opportunity to own some of the world's best businesses at a steep discount to fair value.Hilton is one of those businesses. Hilton stock is one of those names priced at a discount. Don't PanicIt's understandable why investors have sold Hilton stock. Panic still grips this market, even with a recent bounce. The volatility index, often referred to as the VIX, still sits above 50 -- a hugely elevated level.And like other hotels, Hilton is seeing a significant short-term reduction in demand. One industry analyst estimated that RevPAR (revenue per available room) was down a stunning 80% last week.There are mid-term worries as well. Some investors clearly are worried that a recession will follow even once the coronavirus is under control. And Hilton unsurprisingly struggled during the financial crisis.According to the prospectus filed at the time of its 2013 initial public offering, revenue declined almost 15% in 2009. Excluding non-cash impairments, operating profit fell by almost half.Hilton is going to take a hit. But that's true of most companies in the short term. There are exceptions like Zoom Video Technologies (NASDAQ:ZM), or a biotech like Moderna (NASDAQ:MRNA) that is working on a coronavirus vaccine. A travel-based company like Hilton, however, simply is going to have to make it through to the other side. Look at HistoryAnd Hilton will make it through to the other side. Bear in mind that the company is a franchisor, which significantly minimizes its exposure to hotel-level operating losses during this pandemic.Hilton did close 2019 with almost $8 billion in debt. But with a market capitalization still over $18 billion and the power of the Hilton brand, those liabilities are manageable.Meanwhile, travel will bounce back. And corporate travel should do so first. That's Hilton's sweet spot.We've seen what happens with hotel stocks in a recovery. Hilton was private during the financial crisis: Blackstone Group (NYSE:BX) led a leveraged buyout in 2007. But peers were among the best stocks to buy at -- or even before -- the March 2009 bottom.Marriott (NASDAQ:MAR) more than tripled in 20 months. Hyatt (NYSE:H) executed an IPO in late 2009 and the stock almost doubled in 15 months. The Case for Hilton StockI'm not guaranteeing that Hilton stock will see similar returns. But in a recovery, hotel stocks do well. And Hilton stock may well be the best hotel stock out there.Certainly, in this volatile market, position sizing matters. Investors need to do their due diligence. And it's possible HLT sees further declines.But, as is always the case, investors need to take the long view. This is one of the world's great companies. Its stock price is down by almost half.At some point, one of those two things will change. It won't be the quality of Hilton's business.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. Matt does not directly own the aforementioned securities. More From InvestorPlace * 25 Stocks You Should Sell Immediately * 1 Under-the-Radar 5G Stock to Buy Now * This Stock Picker's Latest Video Just Went Viral * The 1 Stock All Retirees Must Own The post Hilton Stock Will Rally Once This Crisis Passes appeared first on InvestorPlace.

    • Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In
      Zacks

      Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In

      Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.

    • Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?
      Zacks

      Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?

      Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

    • Moderna Coronavirus Vaccine Phase 2 Trials Could Start In Spring, Chairman Says
      Benzinga

      Moderna Coronavirus Vaccine Phase 2 Trials Could Start In Spring, Chairman Says

      The second phase of the clinical trials of the novel coronavirus (COVID-19) vaccine of Moderna Inc. (NASDAQ: MRNA) could begin in spring, the biotechnology company's chairman Noubar Afeyan told CNBC on Thursday.What Happened "It's difficult to put a specific date on things just because it's a very dynamic situation," Afeyan said. "We've entered phase 1 trials. ... We'll enter hopefully phase 2 trials, we expect that to happen in the spring, perhaps early summer," Afeyan said. "And success there will hopefully lead us to phase 3 trials."Moderna's phase one clinical trial started on March 16, in collaboration with the National Institute of Health.White House Coronavirus Task Force member Anthony Fauci on Wednesday said that the trials were "on track," and the vaccine, if approved for use, could be available in the next 12 to 18 months.Other companies, including Johnson & Johnson (NYSE: JNJ) and Inovio Pharmaceuticals Inc. (NASDAQ: INO), have been working on developing their coronavirus vaccines as well.Afeyan told CNBC that Moderna hoped "that everybody succeeds because the worldwide demand for these types of interventions is far in excess of what any one player can deliver."Price Action Moderna's shares closed 11.9% higher at $33.20 on Thursday. The shared traded 0.27% lower at $33.11 in the after-hours session.See more from Benzinga * Tesla Is 'Crushing The Auto Industry', Munster Says, As Company Posts Q1 Delivery Figures * FTC Seeks To Undo Altria's .8B Juul Investment, Says It Violated Antitrust Laws * Disney+ Makes Middle East Debut Through Third-Party Network(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Recovering From the Coma
      GuruFocus.com

      Recovering From the Coma

      The patient, the US economy, is sick and remains in a coma Continue reading...

    • The Zacks Analyst Blog Highlights: Moderna, Regeneron, Zoom Video, Netflix and Peloton
      Zacks

      The Zacks Analyst Blog Highlights: Moderna, Regeneron, Zoom Video, Netflix and Peloton

      The Zacks Analyst Blog Highlights: Moderna, Regeneron, Zoom Video, Netflix and Peloton

    • Coronavirus Vaccine Race Intensifies: 3 Stocks in Focus
      Zacks

      Coronavirus Vaccine Race Intensifies: 3 Stocks in Focus

      Given the urgent need for preventing the spread of COVID-19 in future, let's take a look at the companies developing vaccines for the same.

    • With $1.1B in hand, life sciences investor Flagship rewrites its rulebook
      American City Business Journals

      With $1.1B in hand, life sciences investor Flagship rewrites its rulebook

      The Cambridge-based company set out to raise its seventh so-called Opportunity Fund in mid-January and managed to pull together $1.1 billion in funding within two months.

    • Medical Sector In Focus Amid Testing, Treatment & Vaccine Efforts
      Investor's Business Daily Video

      Medical Sector In Focus Amid Testing, Treatment & Vaccine Efforts

      All hands are on deck in the medical sector amid the scramble for testing, treatments and vaccines for Covid-19. IBD tech reporter Allison Gatlin provides a detailed investor overview.